Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

24.90-0.0700-0.28%Vol 24.39K1Y Perf 40.48%
Apr 9th, 2021 15:52 DELAYED
BID24.90 ASK24.99
Open24.94 Previous Close24.97
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★★ —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap- 
Earnings Rating
Price Range Ratio 52W %
98.27 
Earnings Date
-

Today's Price Range

24.7325.05

52W Range

15.8225.06

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
3.58%
1 Month
11.36%
3 Months
24.31%
6 Months
30.09%
1 Year
40.48%
3 Years
11.86%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FBIOP24.90-0.0700-0.28
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume24.39K
Shares Outstanding0
Trades Count154
Dollar Volume164.67K
Avg. Volume21.40K
Avg. Weekly Volume17.62K
Avg. Monthly Volume18.91K
Avg. Quarterly Volume21.42K

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP) stock closed at 24.9 per share at the end of the most recent trading day (a -0.28% change compared to the prior day closing price) with a volume of 24.39K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 93 people. Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock CEO is Lindsay A. Rosenwald.

The one-year performance of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock is 40.48%, while year-to-date (YTD) performance is 28.42%. FBIOP stock has a five-year performance of %. Its 52-week range is between 15.82 and 25.06, which gives FBIOP stock a 52-week price range ratio of 98.27%

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 4.40, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -16.17%, a ROC of -26.69% and a ROE of -72.20%. The company’s profit margin is -%, its EBITDA margin is -218.70%, and its revenue ttm is $18.93 Million , which makes it $5.52 revenue per share.

Of the last four earnings reports from Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock’s next earnings report date is -.

The consensus rating of Wall Street analysts for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has a dividend yield of 9.64% with a dividend per share of $2.34 and a payout ratio of -%.

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has a Buy technical analysis rating based on Technical Indicators (ADX : 15.21, ATR14 : 0.82, CCI20 : -113.99, Chaikin Money Flow : -0.04, MACD : 0.11, Money Flow Index : 31.24, ROC : -3.27, RSI : 49.12, STOCH (14,3) : 54.17, STOCH RSI : 0.39, UO : 53.57, Williams %R : -45.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock in the last 12-months were: Lindsay A. Rosenwald (Buy at a value of $945 000), Malcolm Hoenlein (Buy at a value of $300 006)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

CEO: Lindsay A. Rosenwald

Telephone: +1 781 652-4500

Address: 2 Gansevoort Street, New York 10014, NY, US

Number of employees: 93

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

Bearish Bullish

56%44%

News

Stocktwits